[go: up one dir, main page]

NO20083026L - Terapeutisk middel for diabetes - Google Patents

Terapeutisk middel for diabetes

Info

Publication number
NO20083026L
NO20083026L NO20083026A NO20083026A NO20083026L NO 20083026 L NO20083026 L NO 20083026L NO 20083026 A NO20083026 A NO 20083026A NO 20083026 A NO20083026 A NO 20083026A NO 20083026 L NO20083026 L NO 20083026L
Authority
NO
Norway
Prior art keywords
diabetes
therapeutic agent
symbol
salt
formula
Prior art date
Application number
NO20083026A
Other languages
English (en)
Inventor
Hajime Takashima
Koji Takeuchi
Yusuke Moritoh
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20083026L publication Critical patent/NO20083026L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår et middel for pankreasbeskyttelse som inneholder en kombinasjon av et blodglukosereduserende legemiddel som ikke stimulerer insulinsekresjon og en forbindelse representert ved formelen (I) hvori hvert symbol er som definert i beskrivelsen, eller et salt derav, eller en forbindelse representert ved formelen (II) hvori hvert symbol er som definert i beskrivelsen, eller et salt derav.
NO20083026A 2005-12-28 2008-07-04 Terapeutisk middel for diabetes NO20083026L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005379407 2005-12-28
JP2006061722 2006-03-07
PCT/JP2006/326141 WO2007074884A1 (ja) 2005-12-28 2006-12-27 糖尿病治療剤

Publications (1)

Publication Number Publication Date
NO20083026L true NO20083026L (no) 2008-09-16

Family

ID=38218106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083026A NO20083026L (no) 2005-12-28 2008-07-04 Terapeutisk middel for diabetes

Country Status (16)

Country Link
US (1) US20090042863A1 (no)
EP (1) EP1970063A4 (no)
JP (1) JP5094416B2 (no)
KR (1) KR20080081354A (no)
AU (1) AU2006330332B2 (no)
BR (1) BRPI0620718A2 (no)
CA (1) CA2635777A1 (no)
GE (1) GEP20105033B (no)
IL (1) IL192369A0 (no)
MA (1) MA30176B1 (no)
ME (1) MEP7609A (no)
MY (1) MY152172A (no)
NO (1) NO20083026L (no)
NZ (1) NZ569661A (no)
RU (1) RU2438671C2 (no)
WO (1) WO2007074884A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110094T8 (en) * 2007-02-01 2011-07-31 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and pioglitazone
KR101536786B1 (ko) * 2007-07-19 2015-07-14 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 메트포르민 히드로클로라이드를 포함하는 고체 제제
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
WO2009139362A1 (ja) 2008-05-14 2009-11-19 株式会社 三和化学研究所 Dpp-iv阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
KR101054911B1 (ko) 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
ES2671069T3 (es) * 2008-12-23 2018-06-04 Sandoz Ag Forma cristalina de la alogliptina
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2521721B1 (en) 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMINE DERIVATIVES
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1228067B1 (en) 1999-11-10 2004-07-14 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
EP1741445B1 (en) * 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
US20050070531A1 (en) 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
GEP20094679B (en) * 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
JP4854511B2 (ja) * 2004-08-26 2012-01-18 武田薬品工業株式会社 糖尿病治療剤
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
MA30176B1 (fr) 2009-01-02
BRPI0620718A2 (pt) 2011-11-22
JP5094416B2 (ja) 2012-12-12
KR20080081354A (ko) 2008-09-09
AU2006330332B2 (en) 2012-03-08
RU2008130878A (ru) 2010-02-10
MY152172A (en) 2014-08-15
RU2438671C2 (ru) 2012-01-10
EP1970063A1 (en) 2008-09-17
WO2007074884A1 (ja) 2007-07-05
IL192369A0 (en) 2011-08-01
NZ569661A (en) 2011-06-30
US20090042863A1 (en) 2009-02-12
EP1970063A4 (en) 2014-05-21
JPWO2007074884A1 (ja) 2009-06-04
AU2006330332A1 (en) 2007-07-05
MEP7609A (en) 2011-12-20
CA2635777A1 (en) 2007-07-05
GEP20105033B (en) 2010-06-25

Similar Documents

Publication Publication Date Title
NO20083026L (no) Terapeutisk middel for diabetes
NO20084919L (no) Oksadiazolidindionforbindelse
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
NO20081196L (no) Terapeutisk middel for diabetes
MX2010009736A (es) Compuesto heterociclico.
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
GEP20146060B (en) Pyridyl inhibitors of hedgehog signalling
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
GEP20115359B (en) Fused cyclic compounds
MX2008000255A (es) Activadores de urea glucocinasa.
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
MX2009009417A (es) Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
NO20074872L (no) Pyrazoler
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
NO20091599L (no) Kjemiske forbindelser
UA83057C2 (ru) Замещенные производные диоксида тиазолбензоизотиазола и их применение

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application